{"aliases":[{"type":"ChemicalStructureName","name":"3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo(2,3-D)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile"},{"type":"CodeName","name":"CP-690,550 free base"},{"type":"CodeName","name":"CP-690550"},{"type":"Synonym","name":"tasocitinib"},{"type":"CASRegistryName","name":"477600-75-2"}],"definition":{"html":"An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.","text":"An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation."},"drugInfoSummaryLink":null,"nciConceptId":"C95800","nciConceptName":"Tofacitinib","termId":759505,"name":"tofacitinib","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tofacitinib"}